EZH2 PROTACs针对EZH2和FOXM1相关的致癌节点,抑制乳腺癌细胞生长
Joshua Corbin1,2, Xufen Yu3,4, Jian Jin3,4
1Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, 27710, USA.
Oncogene
|August 7, 2024
概括
向蛋白质溶解向仿真体 (PROTACs) 向增强器的向同类物2 (EZH2) 通过降解EZH2和FOXM1.1,有效地治疗抗他莫西芬乳腺癌. 这种方法显示出克服治疗耐药性的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌 (BC) 是女性癌症死亡的主要原因.
- 塔莫西芬耐药性是BC治疗中的一个重大临床挑战.
- 增强性同源2 (EZH2) 的增强剂与他莫西芬耐药性有关,其功能既有规范性又有非规范性.
研究的目的:
- 调查EZH2向蛋白质分解向仿真体 (PROTACs) 对抗抗 tamoxifen 耐药乳腺癌的疗效.
- 阐明EZH2 PROTACs的作用背后的分子机制.
主要方法:
- 在乳腺癌细胞模型中利用EZH2 PROTACs (MS177和MS8815),包括对他莫西芬耐药的细胞系.
- 将PROTAC与传统的甲基转移酶抑制剂的疗效进行比较.
- 研究了EZH2和叉盒M1 (FOXM1) 和它们的基因调节之间的相互作用.
主要成果:
- EZH2 PROTACs显著抑制了敏感和耐他莫西芬乳腺癌细胞的生长.
- 与甲基转移酶抑制剂相比,PROTACs显示出更高的疗效.
- EZH2 PROTACs诱导了EZH2和FOXM1的降解,减少了参与细胞循环和他莫西芬耐药性关键基因的表达.
结论:
- EZH2 PROTACs对抗耐坦莫西芬乳腺癌是有效的.
- 通过PROTACs向EZH2降解提供了一个有前途的治疗策略,用于克服乳腺癌治疗耐药性.
- EZH2和FOXM1的双重降解是其作用的关键机制.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer-Critical Genes I: Proto-oncogenes
8.8K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.8K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K


